Expression, purification, and characterization of active recombinant prostate-specific antigen in Pichia pastoris (yeast).
BACKGROUND
Prostate-specific antigen (PSA), a member of the kallikrein family of serine proteases, is a chymotrypsin-like glycoprotein produced by the prostate epithelium. Elevated serum PSA (> 4 ng/ml) is a tumor marker for prostatic cancer and benign prostatic hypertrophy; increasing serum PSA over time is indicative of metastatic disease. It has been suggested that PSA may contribute to tumor metastasis through degradation of extracellular matrix glycoproteins, as well as cleavage of IGF binding protein-3, a modulator of IGF-1. To elucidate the role of PSA in the development and progression of prostatic cancer, it is necessary to have a reliable, cost-effective source of enzymatically active protein. Previous efforts to express recombinant PSA (rPSA) produced inactive proPSA, or mixtures of active and inactive PSA requiring activation by removal of the propeptide. We describe the expression of active recombinant mature PSA in yeast.


METHODS
Stable chromosomal integration of a construct consisting of the yeast alpha-factor signal sequence preceding the mature PSA sequence resulted in secretion of rPSA. The rPSA was purified from the yeast cell culture supernatant to homogeneity by strong cation-exchange chromatography, and characterized by SDS-PAGE, Western analysis, electrospray mass spectrometry, N-glycanase digestion, N-terminal amino acid sequencing, and inactivation by a PSA-specific inhibitor.


RESULTS
We report the production of active, mature rPSA in Pichia pastoris. Two forms of rPSA varying slightly in glycosylation were identified. The specific activity of the rPSA was equal to that of human seminal plasma PSA (0.56 micromol/min mg) as determined using a chromogenic substrate.


CONCLUSIONS
Large-scale production of active rPSA will be useful in the exploration of PSA effects on tumor cell proliferation, migration and metastasis. In addition, a large supply of enzyme should facilitate the discovery of novel inhibitors for in vitro and in vivo evaluation, and may provide a reproducible source of rPSA for use as a standard in diagnostic testing.
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. lhabeck@lilly.com
L L
LL
Habeck
R M
RM
Belagaje
G W
GW
Becker
J E
JE
Hale
L M
LM
Churgay
M
M
Ulmer
X Y
XY
Yang
K A
KA
Shackelford
J M
JM
Richardson
M G
MG
Johnson
L G
LG
Mendelsohn
D000581:Amidohydrolases / Q000378:metabolism; D015153:Blotting, Western; D017931:DNA Primers; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism*; D004274:DNA, Recombinant / Q000235:genetics / Q000378:metabolism*; D015966:Gene Expression Regulation, Fungal; D015972:Gene Expression Regulation, Neoplastic; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D043524:Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; D010843:Pichia; D016133:Polymerase Chain Reaction / Q000379:methods; D017430:Prostate-Specific Antigen / Q000096:biosynthesis* / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics / Q000276:immunology*; D021241:Spectrometry, Mass, Electrospray Ionization
D017931:DNA Primers; D004273:DNA, Neoplasm; D004274:DNA, Recombinant; D017430:Prostate-Specific Antigen; D000581:Amidohydrolases; D043524:Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase